TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children
Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this type of leukemia is another manifestation of Li-Fra...
Saved in:
| Published in | Journal of clinical oncology Vol. 36; no. 6; pp. 591 - 599 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society of Clinical Oncology
20.02.2018
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0732-183X 1527-7755 1527-7755 |
| DOI | 10.1200/JCO.2017.75.5215 |
Cover
Loading…
| Abstract | Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this type of leukemia is another manifestation of Li-Fraumeni syndrome; however, the pattern, prevalence, and clinical relevance of TP53 variants in childhood ALL remain unknown. Patients and Methods Targeted sequencing of TP53 coding regions was performed in 3,801 children from the Children's Oncology Group frontline ALL clinical trials, AALL0232 and P9900. TP53 variant pathogenicity was evaluated according to experimentally determined transcriptional activity, in silico prediction of damaging effects, and prevalence in non-ALL control populations. TP53 variants were analyzed for their association with ALL presenting features and treatment outcomes. Results We identified 49 unique nonsilent rare TP53 coding variants in 77 (2.0%) of 3,801 patients sequenced, of which 22 variants were classified as pathogenic. TP53 pathogenic variants were significantly over-represented in ALL compared with non-ALL controls (odds ratio, 5.2; P < .001). Children with TP53 pathogenic variants were significantly older at ALL diagnosis (median age, 15.5 years v 7.3 years; P < .001) and were more likely to have hypodiploid ALL (65.4% v 1.2%; P < .001). Carrying germline TP53 pathogenic variants was associated with inferior event-free survival and overall survival (hazard ratio, 4.2 and 3.9; P < .001 and .001, respectively). In particular, children with TP53 pathogenic variants were at a dramatically higher risk of second cancers than those without pathogenic variants, with 5-year cumulative incidence of 25.1% and 0.7% ( P < .001), respectively. Conclusion Loss-of-function germline TP53 variants predispose children to ALL and to adverse treatment outcomes with ALL therapy, particularly the risk of second malignant neoplasms. |
|---|---|
| AbstractList | Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this type of leukemia is another manifestation of Li-Fraumeni syndrome; however, the pattern, prevalence, and clinical relevance of TP53 variants in childhood ALL remain unknown. Patients and Methods Targeted sequencing of TP53 coding regions was performed in 3,801 children from the Children's Oncology Group frontline ALL clinical trials, AALL0232 and P9900. TP53 variant pathogenicity was evaluated according to experimentally determined transcriptional activity, in silico prediction of damaging effects, and prevalence in non-ALL control populations. TP53 variants were analyzed for their association with ALL presenting features and treatment outcomes. Results We identified 49 unique nonsilent rare TP53 coding variants in 77 (2.0%) of 3,801 patients sequenced, of which 22 variants were classified as pathogenic. TP53 pathogenic variants were significantly over-represented in ALL compared with non-ALL controls (odds ratio, 5.2; P < .001). Children with TP53 pathogenic variants were significantly older at ALL diagnosis (median age, 15.5 years v 7.3 years; P < .001) and were more likely to have hypodiploid ALL (65.4% v 1.2%; P < .001). Carrying germline TP53 pathogenic variants was associated with inferior event-free survival and overall survival (hazard ratio, 4.2 and 3.9; P < .001 and .001, respectively). In particular, children with TP53 pathogenic variants were at a dramatically higher risk of second cancers than those without pathogenic variants, with 5-year cumulative incidence of 25.1% and 0.7% ( P < .001), respectively. Conclusion Loss-of-function germline TP53 variants predispose children to ALL and to adverse treatment outcomes with ALL therapy, particularly the risk of second malignant neoplasms. Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this type of leukemia is another manifestation of Li-Fraumeni syndrome; however, the pattern, prevalence, and clinical relevance of TP53 variants in childhood ALL remain unknown. Patients and Methods Targeted sequencing of TP53 coding regions was performed in 3,801 children from the Children's Oncology Group frontline ALL clinical trials, AALL0232 and P9900. TP53 variant pathogenicity was evaluated according to experimentally determined transcriptional activity, in silico prediction of damaging effects, and prevalence in non-ALL control populations. TP53 variants were analyzed for their association with ALL presenting features and treatment outcomes. Results We identified 49 unique nonsilent rare TP53 coding variants in 77 (2.0%) of 3,801 patients sequenced, of which 22 variants were classified as pathogenic. TP53 pathogenic variants were significantly over-represented in ALL compared with non-ALL controls (odds ratio, 5.2; P < .001). Children with TP53 pathogenic variants were significantly older at ALL diagnosis (median age, 15.5 years v 7.3 years; P < .001) and were more likely to have hypodiploid ALL (65.4% v 1.2%; P < .001). Carrying germline TP53 pathogenic variants was associated with inferior event-free survival and overall survival (hazard ratio, 4.2 and 3.9; P < .001 and .001, respectively). In particular, children with TP53 pathogenic variants were at a dramatically higher risk of second cancers than those without pathogenic variants, with 5-year cumulative incidence of 25.1% and 0.7% ( P < .001), respectively. Conclusion Loss-of-function germline TP53 variants predispose children to ALL and to adverse treatment outcomes with ALL therapy, particularly the risk of second malignant neoplasms.Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this type of leukemia is another manifestation of Li-Fraumeni syndrome; however, the pattern, prevalence, and clinical relevance of TP53 variants in childhood ALL remain unknown. Patients and Methods Targeted sequencing of TP53 coding regions was performed in 3,801 children from the Children's Oncology Group frontline ALL clinical trials, AALL0232 and P9900. TP53 variant pathogenicity was evaluated according to experimentally determined transcriptional activity, in silico prediction of damaging effects, and prevalence in non-ALL control populations. TP53 variants were analyzed for their association with ALL presenting features and treatment outcomes. Results We identified 49 unique nonsilent rare TP53 coding variants in 77 (2.0%) of 3,801 patients sequenced, of which 22 variants were classified as pathogenic. TP53 pathogenic variants were significantly over-represented in ALL compared with non-ALL controls (odds ratio, 5.2; P < .001). Children with TP53 pathogenic variants were significantly older at ALL diagnosis (median age, 15.5 years v 7.3 years; P < .001) and were more likely to have hypodiploid ALL (65.4% v 1.2%; P < .001). Carrying germline TP53 pathogenic variants was associated with inferior event-free survival and overall survival (hazard ratio, 4.2 and 3.9; P < .001 and .001, respectively). In particular, children with TP53 pathogenic variants were at a dramatically higher risk of second cancers than those without pathogenic variants, with 5-year cumulative incidence of 25.1% and 0.7% ( P < .001), respectively. Conclusion Loss-of-function germline TP53 variants predispose children to ALL and to adverse treatment outcomes with ALL therapy, particularly the risk of second malignant neoplasms. |
| Author | Zhang, Hui Bowman, W. Paul Mardis, Elaine R. Devidas, Meenakshi Cheng, Cheng Evans, William E. Raetz, Elizabeth Dai, Yunfeng Moriyama, Takaya Carroll, William L. Larsen, Eric Martin, Paul L. Cao, Xueyuan Borowitz, Michael Yang, Wenjian Gastier-Foster, Julie M. Qian, Maoxiang Carroll, Andrew Fulton, Robert Mullighan, Charles G. Loh, Mignon L. Relling, Mary V. Heerema, Nyla A. Zambetti, Gerard Winick, Naomi Wood, Brent Pui, Ching-Hon Yang, Jun J. Hunger, Stephen P. Nichols, Kim E. Xu, Heng |
| Author_xml | – sequence: 1 givenname: Maoxiang surname: Qian fullname: Qian, Maoxiang organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 2 givenname: Xueyuan surname: Cao fullname: Cao, Xueyuan organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 3 givenname: Meenakshi surname: Devidas fullname: Devidas, Meenakshi organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 4 givenname: Wenjian surname: Yang fullname: Yang, Wenjian organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 5 givenname: Cheng surname: Cheng fullname: Cheng, Cheng organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 6 givenname: Yunfeng surname: Dai fullname: Dai, Yunfeng organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 7 givenname: Andrew surname: Carroll fullname: Carroll, Andrew organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 8 givenname: Nyla A. surname: Heerema fullname: Heerema, Nyla A. organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 9 givenname: Hui surname: Zhang fullname: Zhang, Hui organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 10 givenname: Takaya surname: Moriyama fullname: Moriyama, Takaya organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 11 givenname: Julie M. surname: Gastier-Foster fullname: Gastier-Foster, Julie M. organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 12 givenname: Heng surname: Xu fullname: Xu, Heng organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 13 givenname: Elizabeth surname: Raetz fullname: Raetz, Elizabeth organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 14 givenname: Eric surname: Larsen fullname: Larsen, Eric organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 15 givenname: Naomi surname: Winick fullname: Winick, Naomi organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 16 givenname: W. Paul surname: Bowman fullname: Bowman, W. Paul organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 17 givenname: Paul L. surname: Martin fullname: Martin, Paul L. organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 18 givenname: Elaine R. surname: Mardis fullname: Mardis, Elaine R. organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 19 givenname: Robert surname: Fulton fullname: Fulton, Robert organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 20 givenname: Gerard surname: Zambetti fullname: Zambetti, Gerard organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 21 givenname: Michael surname: Borowitz fullname: Borowitz, Michael organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 22 givenname: Brent surname: Wood fullname: Wood, Brent organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 23 givenname: Kim E. surname: Nichols fullname: Nichols, Kim E. organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 24 givenname: William L. surname: Carroll fullname: Carroll, William L. organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 25 givenname: Ching-Hon surname: Pui fullname: Pui, Ching-Hon organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 26 givenname: Charles G. surname: Mullighan fullname: Mullighan, Charles G. organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 27 givenname: William E. surname: Evans fullname: Evans, William E. organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 28 givenname: Stephen P. surname: Hunger fullname: Hunger, Stephen P. organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 29 givenname: Mary V. surname: Relling fullname: Relling, Mary V. organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 30 givenname: Mignon L. surname: Loh fullname: Loh, Mignon L. organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M – sequence: 31 givenname: Jun J. surname: Yang fullname: Yang, Jun J. organization: Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children’s Research Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham, AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and Wexner Medical Center; Julie M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29300620$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1UUtv1DAQtlBRuy2991T5yCWL304uSCWCUrRSeyiIm-U4k64hsRc7qdR_j5e2CJA4jWbme2jmO0YHIQZA6IySNWWEvPnUXq8ZoXqt5VoyKl-gFZVMV1pLeYBWRHNW0Zp_PULHOX8jhIqay0N0xBpOiGJkhe5vbyTHl5Cm0QfAX2zydvYxZHwVhnGB4ADPW8A3CXqfdzH7_Rbb0JdRvAtlkHEc8LuqhXHEF26ZAW8ept02dqPNs3d4A8t3mLzFPuB268c-QXiFXg52zHD6VE_Q5w_vb9uP1eb68qq92FROMDJXg2yEc4w2VAndDIop3fWO2dKJWvXgFB1qoa2kjDkAS4nq-kY0AiTldd3xE_T2UXe3dBP0DsKc7Gh2yU82PZhovfl7E_zW3MV7I2sqBeFF4PWTQIo_FsizmXx25VQbIC7Z0KZuJFdaswI9_9Prt8nzswtAPQJcijknGIzz869vF2s_GkrMPlVTUjX7VI2WZp9qIZJ_iM_a_6X8BOcVpS4 |
| CitedBy_id | crossref_primary_10_1158_1541_7786_MCR_21_0583 crossref_primary_10_1016_S1245_1789_21_44720_7 crossref_primary_10_1111_cas_14238 crossref_primary_10_1097_MPH_0000000000002097 crossref_primary_10_1038_s41375_021_01163_y crossref_primary_10_1007_s11864_022_00963_3 crossref_primary_10_3389_fonc_2024_1361928 crossref_primary_10_1080_00365513_2023_2195682 crossref_primary_10_1038_s41568_020_00315_z crossref_primary_10_3389_fped_2022_1011873 crossref_primary_10_3389_fcell_2021_631946 crossref_primary_10_1182_asheducation_2018_1_301 crossref_primary_10_1200_JCO_23_01392 crossref_primary_10_1186_s12885_023_11513_x crossref_primary_10_1158_1055_9965_EPI_18_0801 crossref_primary_10_1186_s12902_022_01253_7 crossref_primary_10_1016_j_ejcped_2023_100133 crossref_primary_10_3238_arztebl_2018_0848 crossref_primary_10_3389_fonc_2021_640166 crossref_primary_10_1002_cpt_2095 crossref_primary_10_1136_medethics_2020_106656 crossref_primary_10_1016_j_biopha_2019_109399 crossref_primary_10_1080_10428194_2019_1660965 crossref_primary_10_1007_s11899_021_00636_2 crossref_primary_10_1182_blood_2020009895 crossref_primary_10_1053_j_semdp_2023_11_004 crossref_primary_10_1101_cshperspect_a034835 crossref_primary_10_1007_s10147_021_02011_w crossref_primary_10_1002_pbc_28340 crossref_primary_10_1186_s12885_020_6599_8 crossref_primary_10_1200_JCO_2018_77_8589 crossref_primary_10_3390_jcm10092028 crossref_primary_10_3390_diagnostics12030724 crossref_primary_10_1177_2040620720927575 crossref_primary_10_24287_1726_1708_2024_23_3_91_101 crossref_primary_10_1002_pbc_27916 crossref_primary_10_3390_cancers12123498 crossref_primary_10_1038_s41375_025_02535_4 crossref_primary_10_1111_bjh_15590 crossref_primary_10_1155_2022_2712808 crossref_primary_10_3389_fimmu_2018_03136 crossref_primary_10_1007_s11684_020_0759_8 crossref_primary_10_1016_j_jmoldx_2021_07_013 crossref_primary_10_2478_ahem_2023_0023 crossref_primary_10_1182_blood_2018852400 crossref_primary_10_1182_bloodadvances_2018028795 crossref_primary_10_1186_s40164_022_00274_1 crossref_primary_10_1007_s12185_022_03501_x crossref_primary_10_1182_blood_2023023336 crossref_primary_10_1038_s41375_020_0831_z crossref_primary_10_1007_s12672_022_00465_6 crossref_primary_10_3390_cancers13164068 crossref_primary_10_1172_JCI147898 crossref_primary_10_3389_fonc_2023_1299355 crossref_primary_10_1016_j_bneo_2024_100060 crossref_primary_10_1177_10935266251316150 crossref_primary_10_1182_blood_2020006164 crossref_primary_10_1200_JCO_18_00822 crossref_primary_10_3390_ijms25010652 crossref_primary_10_1182_bloodadvances_2021005507 crossref_primary_10_1182_blood_2018_12_891564 crossref_primary_10_7889_hct_20_023 crossref_primary_10_1016_S2352_4642_18_30066_X crossref_primary_10_1016_S1470_2045_19_30031_2 crossref_primary_10_1038_s10038_021_00961_7 crossref_primary_10_1080_08880018_2024_2411321 crossref_primary_10_1016_j_bulcan_2023_11_011 crossref_primary_10_1038_s41598_021_84502_4 crossref_primary_10_3389_fonc_2021_710163 crossref_primary_10_47429_lmo_2025_15_1_1 crossref_primary_10_1038_s41598_021_88449_4 crossref_primary_10_1016_j_cll_2022_04_005 crossref_primary_10_1158_0008_5472_CAN_21_1191 crossref_primary_10_1182_bloodadvances_2019001307 crossref_primary_10_3390_cancers14082000 crossref_primary_10_1158_1078_0432_CCR_24_1165 crossref_primary_10_1182_bloodadvances_2022008563 crossref_primary_10_1093_jnci_djac013 crossref_primary_10_1182_blood_2022015850 crossref_primary_10_1182_bloodadvances_2019000051 crossref_primary_10_3390_cancers16050858 crossref_primary_10_3390_cells11244085 crossref_primary_10_1016_j_cancergen_2022_02_011 crossref_primary_10_1182_blood_2023019804 crossref_primary_10_1016_j_blre_2019_06_001 crossref_primary_10_1038_s41375_024_02173_2 crossref_primary_10_1001_jamapediatrics_2019_3807 crossref_primary_10_1146_annurev_genom_083118_015415 crossref_primary_10_1016_j_exphem_2019_05_003 crossref_primary_10_1200_PO_20_00141 crossref_primary_10_1002_gcc_22765 crossref_primary_10_1002_cnr2_1335 crossref_primary_10_1093_jncics_pkab007 crossref_primary_10_1182_asheducation_2018_1_286 crossref_primary_10_1038_s41431_020_0638_4 crossref_primary_10_1136_bmjopen_2022_070082 crossref_primary_10_1080_23808993_2018_1517026 crossref_primary_10_1136_bcr_2021_246249 crossref_primary_10_1080_17474086_2020_1685866 crossref_primary_10_1016_j_jmoldx_2023_11_001 crossref_primary_10_1038_s41571_018_0136_6 crossref_primary_10_3390_jcm10091926 crossref_primary_10_1182_blood_2024024409 crossref_primary_10_1038_s41375_020_01061_9 crossref_primary_10_1016_j_cca_2021_03_013 crossref_primary_10_1007_s11899_021_00641_5 crossref_primary_10_1016_j_leukres_2024_107569 crossref_primary_10_1186_s40364_024_00676_9 crossref_primary_10_1016_j_jpeds_2018_07_039 crossref_primary_10_1148_rg_230202 crossref_primary_10_1007_s00277_018_3554_8 crossref_primary_10_1038_s41392_022_00924_0 crossref_primary_10_1007_s11764_019_00759_9 |
| Cites_doi | 10.1093/nar/gkt1114 10.1056/NEJMoa1508054 10.1038/leu.2011.302 10.1182/blood.V75.5.1170.1170 10.1101/cshperspect.a026187 10.1038/ng.430 10.1182/blood.V70.1.247.247 10.1093/nar/gkq603 10.1054/bjoc.2000.1167 10.1056/NEJMra1400972 10.1038/ng.2892 10.1200/JCO.2012.47.0500 10.1038/ng.585 10.1053/j.seminhematol.2008.09.007 10.1038/ng.3301 10.1126/science.1905840 10.1200/JCO.2010.30.7405 10.1200/JCO.2015.62.4544 10.1073/pnas.1006981107 10.1038/ng.763 10.1111/j.1365-2141.2004.04948.x 10.1001/jama.297.11.1207 10.1002/humu.22552 10.1182/blood-2013-03-491316 10.1146/annurev-biochem-060815-014710 10.1038/ncomms8553 10.1182/blood-2013-05-500850 10.1038/nsb730 10.1182/blood-2015-02-628800 10.1038/nrc864 10.1038/nrclinonc.2014.41 10.1200/JCO.2011.37.8018 10.1038/nature19057 10.1200/JCO.2015.61.5757 10.1001/jama.2017.0693 10.1200/JCO.2014.59.1636 10.1038/nrc.2016.35 10.1038/nprot.2009.86 10.1073/pnas.1431692100 10.1093/genetics/155.2.945 10.1002/humu.23035 10.1093/nar/gkt1113 10.1182/blood-2016-03-704973 10.1093/nar/gkv1222 10.1126/science.8023157 10.1002/gcc.22163 10.1182/blood-2014-12-580001 10.1182/blood-2014-03-562918 10.1002/0471142905.hg0720s76 10.1182/blood-2006-07-038299 10.1038/ng.2803 10.1038/nrm2395 10.1002/humu.22559 10.1016/S0092-8674(00)81871-1 10.1016/S1470-2045(15)00369-1 10.1056/NEJM199112123252402 10.1073/pnas.0607286103 10.1038/ng.2532 10.1182/blood-2008-01-132837 10.1093/jnci/djt042 10.1038/ng.432 10.1038/nmeth0410-248 10.1146/annurev.biochem.77.060806.091238 10.1038/ng.2754 10.1038/nrc2584 |
| ContentType | Journal Article |
| Copyright | 2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology |
| Copyright_xml | – notice: 2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1200/JCO.2017.75.5215 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | TP53 Germline Variations Influence Prognosis of ALL in Children |
| EISSN | 1527-7755 |
| EndPage | 599 |
| ExternalDocumentID | PMC5815403 29300620 10_1200_JCO_2017_75_5215 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA016058 – fundername: NCI NIH HHS grantid: U10 CA098413 – fundername: NCI NIH HHS grantid: U24 CA114766 – fundername: NCI NIH HHS grantid: U10 CA180886 – fundername: NIGMS NIH HHS grantid: U01 GM092666 – fundername: NIGMS NIH HHS grantid: U01 GM097119 – fundername: NCI NIH HHS grantid: P30 CA021765 – fundername: NCI NIH HHS grantid: U10 CA180899 – fundername: NIGMS NIH HHS grantid: P50 GM115279 – fundername: NCI NIH HHS grantid: U10 CA098543 |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AAQQT AARDX AAWTL AAYEP AAYOK AAYXX ABBLC ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL BYPQX C45 CITATION CS3 DIK EBS EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 K-O KQ8 L7B LSO MJL N9A O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VVN WH7 X7M YFH YQY NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c420t-f594cc21916479f6267bdc2a647486dec61f847a5122ceea106bd9494e51388b3 |
| ISSN | 0732-183X 1527-7755 |
| IngestDate | Thu Aug 21 14:13:27 EDT 2025 Fri Jul 11 08:29:09 EDT 2025 Mon Jul 21 05:54:59 EDT 2025 Thu Apr 24 23:07:47 EDT 2025 Tue Jul 01 02:13:03 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c420t-f594cc21916479f6267bdc2a647486dec61f847a5122ceea106bd9494e51388b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 29300620 |
| PQID | 1989536772 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5815403 proquest_miscellaneous_1989536772 pubmed_primary_29300620 crossref_citationtrail_10_1200_JCO_2017_75_5215 crossref_primary_10_1200_JCO_2017_75_5215 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-02-20 |
| PublicationDateYYYYMMDD | 2018-02-20 |
| PublicationDate_xml | – month: 02 year: 2018 text: 2018-02-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2018 |
| Publisher | American Society of Clinical Oncology |
| Publisher_xml | – name: American Society of Clinical Oncology |
| References | B20 B21 B65 B22 B66 B23 B67 B24 B68 B25 B26 B27 B28 B29 B30 B31 B32 B33 B34 B35 B36 B37 B38 B39 B1 B2 B3 B4 B5 Nichols KE (B10) 2001; 10 B6 B7 B8 B40 B41 B42 B43 B44 B45 B46 B47 B48 B49 Heerema NA (B64) 1999; 94 Chompret A (B9) 2000; 82 B50 B51 B52 B53 B54 B11 B55 B56 B13 B57 B14 B58 B15 B59 B16 B17 B18 B19 B60 B61 B62 B63 |
| References_xml | – ident: B44 doi: 10.1093/nar/gkt1114 – volume: 10 start-page: 83 year: 2001 ident: B10 publication-title: Cancer Epidemiol Biomarkers Prev – ident: B13 doi: 10.1056/NEJMoa1508054 – ident: B23 doi: 10.1038/leu.2011.302 – ident: B62 doi: 10.1182/blood.V75.5.1170.1170 – ident: B6 doi: 10.1101/cshperspect.a026187 – ident: B17 doi: 10.1038/ng.430 – ident: B63 doi: 10.1182/blood.V70.1.247.247 – ident: B43 doi: 10.1093/nar/gkq603 – volume: 82 start-page: 1932 year: 2000 ident: B9 publication-title: Br J Cancer doi: 10.1054/bjoc.2000.1167 – ident: B14 doi: 10.1056/NEJMra1400972 – ident: B45 doi: 10.1038/ng.2892 – ident: B33 doi: 10.1200/JCO.2012.47.0500 – ident: B20 doi: 10.1038/ng.585 – ident: B30 doi: 10.1053/j.seminhematol.2008.09.007 – ident: B60 doi: 10.1038/ng.3301 – ident: B57 doi: 10.1126/science.1905840 – ident: B27 doi: 10.1200/JCO.2010.30.7405 – ident: B35 doi: 10.1200/JCO.2015.62.4544 – ident: B59 doi: 10.1073/pnas.1006981107 – ident: B38 doi: 10.1038/ng.763 – ident: B66 doi: 10.1111/j.1365-2141.2004.04948.x – ident: B31 doi: 10.1001/jama.297.11.1207 – ident: B5 doi: 10.1002/humu.22552 – ident: B19 doi: 10.1182/blood-2013-03-491316 – ident: B53 doi: 10.1146/annurev-biochem-060815-014710 – ident: B21 doi: 10.1038/ncomms8553 – ident: B26 doi: 10.1182/blood-2013-05-500850 – ident: B54 doi: 10.1038/nsb730 – ident: B39 doi: 10.1182/blood-2015-02-628800 – ident: B1 doi: 10.1038/nrc864 – ident: B8 doi: 10.1038/nrclinonc.2014.41 – ident: B28 doi: 10.1200/JCO.2011.37.8018 – ident: B40 doi: 10.1038/nature19057 – ident: B68 doi: 10.1200/JCO.2015.61.5757 – ident: B34 doi: 10.1001/jama.2017.0693 – ident: B41 doi: 10.1200/JCO.2014.59.1636 – ident: B56 doi: 10.1038/nrc.2016.35 – ident: B48 doi: 10.1038/nprot.2009.86 – ident: B42 doi: 10.1073/pnas.1431692100 – ident: B37 doi: 10.1093/genetics/155.2.945 – ident: B4 doi: 10.1002/humu.23035 – ident: B50 doi: 10.1093/nar/gkt1113 – ident: B67 doi: 10.1182/blood-2016-03-704973 – ident: B49 doi: 10.1093/nar/gkv1222 – ident: B51 doi: 10.1126/science.8023157 – ident: B61 doi: 10.1002/gcc.22163 – ident: B15 doi: 10.1182/blood-2014-12-580001 – ident: B29 doi: 10.1182/blood-2014-03-562918 – ident: B46 doi: 10.1002/0471142905.hg0720s76 – ident: B65 doi: 10.1182/blood-2006-07-038299 – ident: B18 doi: 10.1038/ng.2803 – volume: 94 start-page: 4036 year: 1999 ident: B64 publication-title: Blood – ident: B3 doi: 10.1038/nrm2395 – ident: B7 doi: 10.1002/humu.22559 – ident: B2 doi: 10.1016/S0092-8674(00)81871-1 – ident: B24 doi: 10.1016/S1470-2045(15)00369-1 – ident: B32 doi: 10.1056/NEJM199112123252402 – ident: B58 doi: 10.1073/pnas.0607286103 – ident: B11 doi: 10.1038/ng.2532 – ident: B36 doi: 10.1182/blood-2008-01-132837 – ident: B22 doi: 10.1093/jnci/djt042 – ident: B16 doi: 10.1038/ng.432 – ident: B47 doi: 10.1038/nmeth0410-248 – ident: B52 doi: 10.1146/annurev.biochem.77.060806.091238 – ident: B25 doi: 10.1038/ng.2754 – ident: B55 doi: 10.1038/nrc2584 |
| SSID | ssj0014835 |
| Score | 2.5895689 |
| Snippet | Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 591 |
| SubjectTerms | ORIGINAL REPORTS |
| Title | TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29300620 https://www.proquest.com/docview/1989536772 https://pubmed.ncbi.nlm.nih.gov/PMC5815403 |
| Volume | 36 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLaqISFeEIxbuclIaBJi6XJznDyOAhtopUXqIG9R4iRbGUumtUGUv8kf4pzYzmUDBHuJ0tSJU52vx9-xz_lMyHOHxZYAZmAgmzZc384N30-EAfjIOU8CM6-19CYfvP1D933IwsHgZydrqVolI_Hjt3UlV7EqXAO7YpXsf1i2eShcgHOwLxzBwnD8NxvPmPNyD3xrzRU_QdirEtve6a1Hal45O8fiW52epesDMMNOipG8MsY4g7crMGfgYA32LRMg1SjlepBVJ9npIq6LA1Xd9x_4bFNjWRaiN1f_cSEnWSdx-R1Oj9plj3qaNqyyddVi9DWM1KmsMptAjB2fLI8XjWtSk9ufs-KLhrWasbD8ugLcbDGml6J0XirmnehXnHZfUbpB7tgGOJ5QjljKTdsc4gIp8Kv9uBRSUXjtOmUm9wNT4zuTGzJdGjpsuSv2eIr5fnzE2QiYDes2BeOfndZQAo6ExadmO4g2qY2zyZj5wEtRgfaaDbELjhZ7YZN3BOGn3PVV_yy1dg7d71zsHJWqVU992nQpFrqY0tvhSPNb5KYCA92VSL1NBlmxSa5PVPrGJtmaSaH09Tadt3V_y226RWethPr6DvmGyKYa2bRFNm2QTQHZtI9sCsimDbJpmVOJbFojm_aQTTWy6aKgGtl3yeHbN_PxvqF2CDGEa5srI2eBKwQMuqiKF-QQnPMkFXYMn1zfSzPhWTnQrxhYrQ1sMLZML0kDN3AzZjngk5x7ZKMoi-wBobnDcs9MXQg5EtQQjAMO7JZzM-bQlJlDsqMNEAkln4-7uHyNMIy2cU14PI3QehFnEVpvSF40d5xJ6Zi_tH2mbRqBf8dFu7jIymoZYU4jczwA0pDclzZunqbBMSS8Z_2mAWrH978pFse1hrzC6MMr3_mI3Gj_24_Jxuq8yp4AP18lT2u8_wK3i-c3 |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=TP53+Germline+Variations+Influence+the+Predisposition+and+Prognosis+of+B-Cell+Acute+Lymphoblastic+Leukemia+in+Children&rft.jtitle=Journal+of+clinical+oncology&rft.au=Qian%2C+Maoxiang&rft.au=Cao%2C+Xueyuan&rft.au=Devidas%2C+Meenakshi&rft.au=Yang%2C+Wenjian&rft.date=2018-02-20&rft.pub=American+Society+of+Clinical+Oncology&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=36&rft.issue=6&rft.spage=591&rft.epage=599&rft_id=info:doi/10.1200%2FJCO.2017.75.5215&rft_id=info%3Apmid%2F29300620&rft.externalDocID=PMC5815403 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |